Lawsuit Faults The Wall Street Journal for Blaming Mindbloom in Matthew Perry’s Death
Mindbloom files defamation lawsuit against The Wall Street Journal for publishing false headline and distorting client stories.
AUSTIN, TEXAS—June 2, 2025—Mindbloom, the largest provider of psychedelic medicine, today filed an $88 million defamation lawsuit in the Superior Court of Delaware against Dow Jones & Company, publisher of The Wall Street Journal (WSJ).
The suit targets a WSJ article that falsely blamed Mindbloom in the death of actor Matthew Perry with the headline “Matthew Perry overdosed on anesthetic that Mindbloom is sending by mail.”
WSJ knew Matthew Perry was never a Mindbloom client, and moments before publishing the headline, the reporter explicitly stated in writing, “We will mention Matthew Perry’s death given the recent news about the arrests. We aren't suggesting that Mindbloom was affiliated with his case.”
Two clients featured in the story also contacted Mindbloom, saying the article completely distorted their experiences and that Mindbloom transformed their lives.
“Clickbait like this isn’t journalism—it's the weaponization of stigma,” said Mindbloom Founder and CEO Dylan Beynon. “I lost my mom and sister to mental illness. When fearmongering headlines scare patients away from life-saving treatment, the cost is measured in suicides, overdoses, and broken families. This lawsuit is about defending our clients and increasing access to effective mental health care.”
The lawsuit details how WSJ:
- Published an article falsely blaming Mindbloom in the death of Matthew Perry after acknowledging that Mindbloom had no connection to his death.
- Assigned the story to an inexperienced summer intern who distorted client stories and used them as clickbait.
- Quoted competitors and their paid consultants without disclosing conflicts of interest.
- Ignored peer-reviewed clinical outcomes and client interviews in order to push an alarmist narrative about at-home ketamine therapy.
“The First Amendment does not shield lies,” said Mindbloom’s counsel Daniel P. Watkins of Meier Watkins LLP. “The Wall Street Journal knew the truth, ignored it, and printed the falsehood anyway. Now it will answer for that choice.”
Over 68 million Americans face mental illness each year. Treatments like antidepressants and talk therapy barely outperform placebos, and 80% of patients relapse within five years.
Founded in 2018, Mindbloom has facilitated over 650,000 guided at-home ketamine therapy sessions. The company also published the two largest peer-reviewed clinical studies in psychedelic medicine history in the Journal of Affective Disorders: 89% of participants reported symptom improvement, fewer than 5% reported side effects—compared with up to 50% for antidepressants.
Mindbloom will continue expanding access to safe, effective mental health care. When inaccurate media coverage deters people from seeking transformational treatment, the company will correct the record, share clinical findings, and amplify client voices.
You can read the full complaint here.
About Mindbloom:
Mindbloom is the largest provider of psychedelic medicine, facilitating more than 650,000 sessions across 36 states. Mindbloom offers guided at-home ketamine therapy for depression, anxiety, and PTSD, with comprehensive programs that combine evidence-based medicine with coaching, content, and community. For more information, visit www.mindbloom.com.
Media Contact
Anna Gotskind
press@mindbloom.com
This article is for informational purposes only and is not intended to be a substitute for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. If you are in a life-threatening situation, call the National Suicide Prevention Line at +1 (800) 273-8255, call 911, or go to the nearest emergency room.
More articles
